Holen Sie sich die Stockscreener-App
0.3265
1.90%
-0.0058
Schlusskurs vom Vortag:
$0.3323
Offen:
$0.3321
24-Stunden-Volumen:
1.59M
Relative Volume:
0.24
Marktkapitalisierung:
$6.17M
Einnahmen:
$2.47M
Nettoeinkommen (Verlust:
$-24.73M
KGV:
-0.0775
EPS:
-4.213
Netto-Cashflow:
$-20.36M
1W Leistung:
-13.39%
1M Leistung:
-57.95%
6M Leistung:
-91.84%
1J Leistung:
-97.44%
1-Tages-Spanne:
$0.3229
$0.3609
1-Wochen-Bereich:
$0.3229
$0.3705
52-Wochen-Spanne:
$0.3229
$14.80
VolitionRX Ltd Stock (VNRX) Company Profile
Firmenname
VolitionRX Ltd
Sektor
Branche
Telefon
646 650 1351
Adresse
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, NTRA, IQV, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.3264 | 6.28M | 2.47M | -24.73M | -20.36M | -4.213 |
TMO
Thermo Fisher Scientific Inc
|
605.36 | 222.97B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
204.87 | 144.27B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
328.30 | 46.72B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
254.97 | 42.67B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
145.07 | 41.40B | 7.23B | 1.41B | 1.09B | 4.979 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-01 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-02-17 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-05-16 | Eingeleitet | Maxim Group | Buy |
| 2018-05-14 | Bestätigt | The Benchmark Company | Buy |
| 2016-09-07 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-02-01 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
VolitionRX Ltd Aktie (VNRX) Neueste Nachrichten
Dilution risk flagged as VolitionRx (NYSE: VNRX) registers more Lind shares for resale - Stock Titan
VolitionRx (NYSE: VNRX) details Lind note and warrant stake under 4.99% cap - Stock Titan
VNRX - Finviz
Fatima Dickey Pushes for Changes at VolitionRx with 7.4% Stake - TradingView
$11M VolitionRx (VNRX) stake comes with call to cut executive pay - Stock Titan
VolitionRx Removes $10M Annual Cap on ATM Sales Via Lind Waiver - Minichart
$VolitionRX (VNRX.US)$ it be like that. not even tripping cuz! - Moomoo
VolitionRx Files for Secondary Offering of Common Shares - Moomoo
This $21 Stock Has CRAZY Potential Baby Sleep (NynJ4YJi1C) - Mshale
Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results - sahmcapital.com
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations - Benzinga
$VolitionRX (VNRX.US)$ - Moomoo
VolitionRx revenue rises 112% in H1FY26; shares surge 100% - scanx.trade
Volition's sepsis biomarker predicts 28-day death and kidney treatment needs - Stock Titan
VolitionRX Ltd (VNRX) (Q2 2026) Earnings Call Highlights: Strate - GuruFocus
Benchmark reiterates Hold on VolitionRX stock amid cost cuts - Investing.com
Benchmark reiterates Hold on VolitionRX stock amid cost cuts By Investing.com - Investing.com Canada
VNRX Looks 97.6% Undervalued on GF Value™ - GuruFocus
Lagoda Investment discloses 14.0% VolitionRX (VNRX) stake in amended Schedule 13G - Stock Titan
Teleconferência de Resultados do 2º Trimestre de 2026 da VolitionRx (VNRX): Custos Caem à Medida que o Pipeline Nu.Q Avança - TradingKey
Conferencia de resultados del Q2 de 2026 de VolitionRx (VNRX): los costos caen a medida que avanza la cartera de desarrollo de Nu.Q - TradingKey
VolitionRx (VNRX) Q2 2026 Ergebniskonferenz: Kosten sinken bei Fortschritten der Nu.Q-Pipeline - TradingKey
Volitionrx Ltd earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Transcript : VolitionRx Limited, Q2 2026 Earnings Call, Aug 14, 2026 - marketscreener.com
Earnings call transcript: VolitionRX misses Q2 2026 estimates as shares slip - Investing.com Canada
VolitionRX Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
VolitionRx Limited Q2 2026 Earnings Call Summary - Yahoo Finance
VolitionRx Q2 Revenue Flat, but Licensing Talks and $5M Milestone Ahead - Minichart
VolitionRx targets $3.8B sepsis market with Nu.Q NETs platform - scanx.trade
VolitionRX: Q2 Earnings Snapshot - marketscreener.com
VolitionRx Q2 2026: Operating expenses fall 32% to $4.6 million - scanx.trade
Form 8K Volitionrx Ltd For: 13 August By Investing.com - Investing.com Nigeria
Form 8K Volitionrx Ltd For: 13 August - Investing.com India
VolitionRx (VNRX) flags going concern risk amid $14M loss and NYSE plan - Stock Titan
VolitionRx Limited (NYSE: VNRX) doubles H1 2026 revenue and trims losses - Stock Titan
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update - Moomoo
Earnings To Watch: VolitionRX Ltd (VNRX) Q2 2026 -- GF Value Sees 3914% Upside - Yahoo Finance
VolitionRx Limited (VNRX) stock price, news, quote and history - Yahoo Finance UK
VolitionRx tests finger-prick sepsis prototype in patients - Investing.com Nigeria
VolitionRx tests finger-prick sepsis prototype in patients By Investing.com - Investing.com Australia
VolitionRx Limited Demonstrates Utility of Rapid Point-Of-Care Finger-Prick Test in Sepsis Patients - marketscreener.com
VolitionRx lateral flow test correlates with legacy assay in sepsis patients - scanx.trade
VolitionRx call will cover Q2 results and upcoming milestones - Stock Titan
VolitionRx to discuss Q2 2026 results and busin... - Pluang
5 Stocks To BUY HEAVY In Early August 2026 Cat Deeley (ii210v0TXj) - Mshale
VolitionRX Ltd (VNRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
VolitionRx issues 779,371 shares to Lind Global to meet convertible note obligations - Bitget
Volition's early liquid biopsy study detected 49 of 49 cancers - Stock Titan
VolitionRx publishes Capture-Seq paper targeting $36B market - scanx.trade
VolitionRx reports data on sepsis biomarker test By Investing.com - Investing.com Canada
VolitionRX Ltd (VNRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Finanzdaten der VolitionRX Ltd-Aktie (VNRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.16%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):